MedPath

Psychological barriers of opioid analgesics and pain in patients with advanced recurrent cancer - A multicenter cohort study

Not Applicable
Conditions
advanced recurrent cancer
Registration Number
JPRN-UMIN000042443
Lead Sponsor
Tokyo University of Pharmacy and Life Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who are considered difficult to collect ePRO (e.g., do not have a smartphone or cannot use a tablet) 2. Patients who have cognitive problems that make it difficult to respond to PROs 3. Patients who have mental health issues that make it difficult to answer the PROs 4. Patients whose primary mechanism of pain is neuropathic pain 5. Patients deemed unfit by a physician

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total JBQ-II score, subscales: barriers related to physiological effects (distrust of symptomatic treatment), barriers related to fatalism (fatalistic resignation), barriers related to communication (disinclination), barriers related to harmful effects (fear of side effects), barriers related to disease progression (from disease We calculated the mean and point estimates of the scores of the (escape defense) scale, and estimated the 95% confidence intervals. In addition, we will classify all observations into groups using the PGI-S, which was installed as an anchor, and estimate the 95% confidence intervals by calculating the mean and point estimates of the total score and the score of the association scale in each group.
Secondary Outcome Measures
NameTimeMethod
Scores of JBQ-II for baseline, JBQ-II for Visit 2 and DRS Change in baseline and Visit 2 in JBQ-II scores Percentage of PPGs achieved through Day 7 The JBQ-II score or Anchor was used to classify the groups, and the differences in DRS score and PPG achievement rate between the two groups were estimated and tested.
© Copyright 2025. All Rights Reserved by MedPath